

Review of Literature Mania Disorder

Sarita Verma¹, Ayush Raj², Soniya³, SP Subashini⁴

Abstract

Bipolar disorder, mania is a maladaptive response to loss and has been referred to as the "mirror image of depression". Genetic influences have been strongly implicated in the development of the disorder. Various other physiological factors, such as biochemical and electrolyte alterations, as well as cerebral structural changes, have been implicated. Side effects of certain medications may also induce symptoms of mania. No single theory can explain the etiology of bipolar disorders, and it is likely that the illness is caused by a combination of factors. Symptoms of mania may be observed on a continuum of three phases, each identified by the extent of severity: phase I, hypomania; phase II, acute mania; and phase III, delirious mania.

Keywords: Bipolar disorder; Mania disorder; Genetic influences; hypomania.

How to cite this article:

Sarita Verma, Ayush Raj, Soniya, SP Subashini/Review of Literature Mania Disorder/RFP Indian Journal of Medical Psychiatry. 2022; 5(1): 13-15.

Introduction

Bipolar disorder is characterized by mood swings from profound depression to extreme to euphoria (mania), with the intervening periods of normality. Delusions or hallucinations may or may not be a part of the clinical picture and onset of symptoms may reflect a seasonal pattern.

A somewhat milder representation of this clinical symptoms picture is called Hypomania. Hypomania is not severe enough to cause marked impairment in social or occupational functioning or to require hospitalizations, and it does not include psychotic features.

Bipolar disorder is a serious illness associated with significant psychosocial morbidity and excess mortality. Recent research carried out by world health organization initiative in community adults from 11 countries worldwide indicated that bipolar

disorder, when defined to include milder variants such as bipolar II disorder and subthreshold bipolar disorder, has a lifetime prevalence of 2.4%.

Definition

Mania is a distinct period which there is an abnormally and persistently elevated, expansive and irritable mood.

This period of abnormal mood must last at least 1 week and present most of the day, nearly every day (Or any duration if hospitalization is necessary).

Etiology: Neurotransmitter and structural hypotheses.

- Elevated Norepinephrine and dopamine

- Genetic consideration

- Higher risk in monozygotic twins.
- First degree relatives 5-10%

Author's Affiliation: ¹BSc. Nursing 3rd year, ²Associated Professor, ³Dean of School of Nursing, Galgotias University, Greater Noida, Uttar Pradesh 203201, India.

Correspondence Author: Ayush Raj, BSc. Nursing 3rd year, Galgotias University, Greater Noida, Uttar Pradesh 203201, India. **E-mail:** ayushraj12112001@gmail.com

Received on: 14.02.2022, **Accepted on:** 22.03.2022

- Identical twin (monozygotic) with bipolar disorders 40-70%.
- Psychodynamic theories
- Faulty family dynamics theory early life.
 - Defense or denial of depression.

Affected symptoms

- *Euphoria (stage I)*: Increase sense of psychological well being and happiness not in keeping with ongoing events.
- *Elation (stage II)*: Moderate elevation of mood with increased psychomotor activity.
- *Exaltation (stage III)*: Intense elevation of mood with delusions of grandeur.
- *Ecstasy (stage IV)*: Severe elevation of mood, intense of rapture or blissfulness seen in delirious or stuporous mania.

Symptom

- Feeling very happy
- Talking very quickly
- Feeling self important
- Suicidal thoughts
- Waking up early
- Feelings of guilt and despair
- Self doubt
- Difficulty in sleeping

Treatment

Antipsychotics drugs: quetiapine, ziprasidone, and aripiprazole.

- Pharmacotherapy
- *Lithium*: 900 - 2100 mg/day
 - *Carbamazepine*: 600 - 1800 mg/day
 - *Sodium valproate*: 600 - 2600 mg/day .
 - *Others drugs*: Clonazepam, calcium channel blockers etc.
- Electroconvulsive Therapy (ECT).
- Psychosocial Treatment
- Family and marital therapy

Material and Methods

The study was conducted in Vimhans hospital in Delhi. It was a cross-sectional descriptive study for which we used purposive sampling technique according to certain inclusion and exclusion criteria. The study included bipolar-I patients (according to DSM-IV criteria) that had a ≥ 2-year history of either lithium or valproate prophylaxis as monotherapy. The

response rate in the patients with unipolar mania and classical bipolar disorder were compared. Then, the response rate to lithium in all the patients with a manic episode rate <50% and >50%, and <80% and >80% during their course were compared. Finally, the above comparisons were repeated, excluding the patients with unipolar mania.

Discussion

Traditionally, observed rates: scales have been used to measure manic states only more recently. The latter have the advantage of being able to assess the patient's internal states and avoiding possible misinterpretation of clinicians, although some authors argued that their subjective nature makes them at risk of exaggeration or understatement of symptoms.

In contrast, in routine clinical practice no one would argue that rating scales eliminate the need for a competent psychiatric evaluation, considering that there are no special questions on the scales that are unfamiliar to a competent clinician. Nonetheless, scales are very useful in clinical practice when it comes to making sure that specific and standardized questions (e.g. suicidal ideation) are consistently asked and recorded.

Moreover, evidence that the administration of rating scales might improve the efficiency of diagnostic evaluation outside clinical trials (characterized by well-defined inclusion/exclusion criteria) is still controversial [30, 28, 51]. In particular, two potential negative consequences have been commonly reported with the systematic assessment provided by self-rating scales for mania in clinical settings. On the one hand, the sensitivity of several instruments is around 60-65%, and clinicians who rely on screening scales that use the first stage in a two-stage process for diagnosing bipolar disorders are at high risk of missing the correct diagnosis in approximately one-third of patients.

Conclusion

Once an accurate diagnosis is established, hypomania and mania associated with bipolar I disorder need to be managed effectively. Depending on patient characteristics, support systems, and the acuity of the episode, the treatment may be administered in an ambulatory or hospital setting.

In assessing risk factors, it is important to consider marital status, gender, age, religion, socioeconomic status, ethnicity, occupational, precipitating stressors, coping strategies, seriousness of intent and lethality and availability of method.

Treatment of mood disorders includes individual, group, family, and cognitive therapies. Somatic therapies include psychopathology and ECT. Nursing care is accomplished using the six steps of nursing process.

References

1. Merikangas KR, Jin R, He JP, et al. Prevalence and Cor-relates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. *Arch Gen Psychiatry* 2011;68:241.
2. Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid- stream from a French national multi-site study (EPI-DEP). *J Affect Disord* 1998;50:163-73.
3. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. *J Clin Psychiatry* 2000;61:804-8
4. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. *Can J Psychiatry* 2002;47:125-34.
5. Zimmerman M, Ruggero CJ, Chelminski I, et al. Is bipolar disorder overdiagnosed? *J Clin Psychiatry* 2008;69:935-40.
6. Lish J, Dime-Meenan S, Whybrow P, et al. The National De- pressive and Manic-depression Association (DMDA) survey of bipolar members. *J Affect Disord* 1994;31:281-94
7. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spec-trum disorder: the Mood Disorder Questionnaire. *Am J Psy-chiatry* 2000;157:1873-5.
8. Birnbaum HG, Shi L, Dial E, et al. Economic consequences of not recognizing bipolar disorder patients: a cross-section-al descriptive analysis. *J Clin Psychiatry* 2003;64:1201-9
9. Shi L, Thiebaud P, McCombs JS. The impact of unrecog-nized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medi- Cal) program. *J Affect Disord* 2004;82:373-83.
10. Matza LS, Rajagopalan KS, Thompson CL, et al. Misdiag-nosed patients with bipolar disorder: comorbidities, treat-ment patterns, and direct treatment costs. *J Clin Psychiatry* 2005;66:1432-40.